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Abstract 
Palmitoylation (S-acylation) is the reversible conjugation of a fatty acid (usually C16 palmitate) 
to intracellular cysteine residues of proteins via a thioester linkage. Palmitoylation anchors 
intracellular regions of proteins to membranes because the palmitoylated cysteine is recruited 
to the lipid bilayer. NCX1 is palmitoylated at a single cysteine in its large regulatory intracellular 
loop. The presence of an amphipathic a-helix immediately adjacent to the NCX1 palmitoylation 
site is required for NCX1 palmitoylation. The NCX1 palmitoylation site is conserved through 
most metazoan phlya. Although palmitoylation does not regulate the normal forward or reverse 
ion transport modes of NCX1, NCX1 palmitoylation is required for its inactivation: sodium-
dependent inactivation and inactivation by PIP2 depletion are significantly impaired for 
unpalmitoylatable NCX1. Here we review the role of palmitoylation in regulating NCX1 activity, 
and highlight future questions that must be addressed to fully understand the importance of 
this regulatory mechanism for sodium and calcium transport in cardiac muscle. 
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1. Roles of NCX1 in cardiac tissue 
1.1 NCX1 and cardiac physiology 
Cardiac diastole (and consequently ventricular filling) relies on the effective removal of Ca 
from the cytoplasm of ventricular myocytes to allow relaxation. This Ca removal occurs as a 
balanced competition governed by the activities of the intracellular Ca ATPase (SERCA 2a) 
and the surface membrane Na/Ca exchanger (NCX1). SERCA 2a stores Ca in the 
sarcoplasmic reticulum and NCX1 is the primary means to extrude Ca into the extracellular 
space [1]. NCX1 splice variants are widely expressed in both excitable and non-excitable 
tissues. NCX1.1 is the major Na/Ca exchanger in cardiac muscle [2]. 
In large mammals, SERCA mediates ~70% and NCX ~30% of Ca removal for a single Ca 
transient [3]. NCX can operate in either forward (Ca extrusion) or reverse (Ca influx) modes, 
depending on membrane potential, the prevailing Na gradient, and the subsarcolemmal free 
Ca concentration. For example at the start of the cardiac action potential (shortly after opening 
of voltage sensitive Na channels) when the membrane potential is positive but before 
substantial accumulation of intracellular Ca, NCX1 briefly operates in reverse mode and 
contributes to the initial Ca influx, triggering Ca release from the sarcoplasmic reticulum [4, 5]. 
As intracellular Ca accumulates later in the action potential, NCX1 operates in forward mode 
and removes intracellular Ca [6]. Balanced Ca flux is an important principal of excitation-
contraction coupling: at steady state Ca entry via voltage gated Ca channels and reverse 
mode NCX1 at the start of the action potential must be balanced by Ca removal by forward 
mode NCX1 activity at the end of the action potential [7].  
Beyond its role in the ventricles, NCX1.1 is also an integral part of the calcium clock, a rhythmic 
generator of action potentials in the sino atrial node (SAN) which relies on the functional 
coupling of surface-localised NCX1 to sarcoplasmic reticulum-localised ryanodine receptors 
(RyR) in SAN cells [8]. This coupling facilitates SAN depolarisation as Ca release following 
synchronised RyR openings generates an inward current through NCX1. Although the relative 
importance of this calcium clock and the membrane clock (generated by the funny current, 
predominantly via HCN4) is hotly debated, they are generally regarded as a coupled system: 
knockout of HCN4 induces bradycardia but does not abolish SAN activity [9], while NCX1 
knockout disturbs but does not silence the node [10]. 
 
1.2 NCX1 and cardiac pathologies 
Contractile abnormalities that occur in left ventricular hypertrophy and heart failure can be 
caused by an imbalance between SERCA and NCX1. Most commonly, depletion of 
intracellular Ca stores (and consequent contractile dysfunction) occurs because either SERCA 
activity is decreased and/or relative NCX1 activity is increased [11, 12]. Whether increased 
NCX1 activity directly contributes to abnormal Ca handling remains uncertain. Genetic 
overexpression of NCX1 does not overtly deplete the SR Ca store [13, 14], and hence does 
not appear to be a direct cause of contractile dysfunction in the absence of haemodynamic 
stress. Nevertheless excess NCX1 activity caused by genetic overexpression does impair the 
ability of L-type Ca channels to evoke SR Ca release, probably as a result of Ca depletion 
from the dyadic cleft by NCX1 [15]. Hence tight regulation of NCX1 activity in this domain is 
clearly key for Ca homeostasis and contractile function. 
Ca removal by NCX1 in forward mode generates a net inward current. These inward currents 
generated by NCX1, especially when its expression / activity is promoted by cardiac 
pathologies, can cause arrhythmogenic delayed afterdepolarizations [11, 16-18]. Indeed, the 
downregulation of SERCA leading to reliance on a calcium handling mechanism that 
generates inward currents late in the cardiac action potential can be regarded as something 
of a ‘perfect storm’ for generation and propagation of arrhythmias. Genetically reducing NCX1 
expression in the heart reduces the incidence of such arrhythmias [19]. Again, this highlights 
the importance of understanding NCX1 regulatory mechanisms and how they may be 
manipulated to minimise the contribution of NCX1 currents to arrhythmias.  
In a setting of ischemia and reoxygenation of ischemic tissue, intracellular Na accumulation 
as a result of Na pump inhibition during ischemia [20, 21] generates a driving force for Ca 
entry via NCX1. Although NCX1 is inhibited by sodium accumulation during ischemia [22], it 
reactivates rapidly during reperfusion, when reverse mode NCX1 activity drives substantial 
intracellular Ca overload, leading to necrotic myocyte death [23]. Cardiac-specific deletion of 
NCX1 protects against ischemia-reperfusion injury [24]. The potential of NCX as a therapeutic 
target is therefore relevant to numerous pathologies, and it has long been recognised as a 
drug target in cardiovascular diseases [24-34]. 
 
2. Protein Palmitoylation/Depalmitoylation 
Cellular proteins undergo a variety of post-translational modifications that can be either static 
or dynamic. These modifications can remarkably extend and modulate the function of the 
proteins by altering their protein and membrane interactions, stability and sorting. 
Palmitoylation (Figure 1) is one of these protein modifications and characterized with a 
reversible attachment of palmitate; 16C saturated fatty acid, onto cysteine(s) (Cys-, C) of a 
target protein via a thioester link [35]. This dynamic biochemical change with the attachment 
of palmitate tunes protein sorting by altering the recruitment of proteins to membranes via the 
palmitoylated cysteine(s) [36]. It is also evident that palmitoylation has a regulatory role in 
protein trafficking at ER - Golgi or protein cycling at endosomes/lysosomes [35-37]. The 
mechanistic process underlying the regulatory effect of palmitoylation on protein sorting could 
be explained as; (1) a simple attachment of palmitate to a target protein enables and facilitates 
portioning of proteins into cholesterol rich lipid rafts [38] and (2) alters the orientation of the 
protein at the plasma membrane, hence affecting the protein-protein interactions [39, 40]. 
 
2.1 Protein-Acyltransferases 
Palmitoylation of proteins is catalysed by protein-acyltransferases (PATs) which were first 
discovered in yeast [41, 42] and subsequently in mammals [43-48]. PATs possess a unique 
Cys-rich Asp-His-His-Cys (DHHC) motif, which is conserved from yeast to mammals and key 
for PAT activity both in vitro and in vivo. Twenty-three isoforms of zDHHC-PATs have been 
identified in humans [49]. Their structure usually accommodates 4 transmembrane (TM) 
domains with a ~50 amino acid conserved cytosolic core between TM2 and TM3 where the 
zDHHC-motif sits. N- and C- terminal domains of zDHHC-PATs, which are diverse, determine 
the substrate selectivity of zDHHC isoforms [49-51]. Furthermore, two members of zDHHC-
PAT family; zDHHC17 and zDHHC13, contain ankyrin repeat (AR) domains at the N terminus. 
These DHHC-PATs are also known as Huntingtin interacting protein 14 (HIP14) and -like 14 
(HIP14L), respectively due to the fact that they interact with and palmitoylate Huntingtin (HTT), 
the protein whose mutation causes Huntington Disease. HIP14/zDHHC17 knockout mice 
develop a range of the neuropathological, progressive behavioural and cognitive deficits 
characteristic of Huntington Disease. [52-55]. The ankyrin repeat domain enables zDHHC17 
and zDHHC13 to interact with proteins possessing a [VIAP][VIT]XXQP consensus, including 
HTT, microtubule associated protein-6, SNAP23 and SNAP25 [56]. To date, various 
substrate/DHHC-PAT pairs have been identified to be critical in neuronal development and 
synaptic plasticity [57]. However, our knowledge on substrate recruitment for zDHHC-PATs in 
the cardiovascular system is limited to the zDHHC5/phospholemman (PLM) interaction. 
zDHHC5 promotes PLM-mediated inhibition of Na pump by palmitoylating PLM at 2 
juxtamembrane cysteines; C40 and C42, in cardiac tissue [51].  
 
2.2 Depalmitoylating Enzymes  
Palmitoylation is a dynamic mechanism and reversed with the removal of palmitate by specific 
depalmitoylating enzymes. In contrast to the large family of palmitoylating enzymes 
determined, there is a small number of depalmitoylating enzymes reported including acyl-
protein thioesterases (APTs; APT1, APT2) and the lysosomal palmitoyl-protein thioesterases 
(PPTs; PPT1, PPT2). Depalmitoylation of membrane bound proteins; HRAS, Gαi, GAP-43., is 
promoted by APT1 and APT2 [58-62]. APT1 and APT2 vary in their substrate-selectivity. For 
instance, APT1 but not APT2 was found to depalmitoylate cysteine domains localized in S0-
S1 loop of large conductance potassium (BK) channels [63]. APT1 was implicated in axon 
survival by facilitating membrane disassociation of axon survival factor Nicotinamide 
Mononucleotide Adenylyltransferase 2 (NMNAT2) [64]. As a result of functional screens to 
uncover neuronal enriched microRNAs (miRNAs), miR-138 was singled out to negatively 
regulate dendritic spine size; however, more strikingly miR-138 targets APT1 Supporting this, 
APT1 knockdown experiments and pharmacological approaches inhibiting APT1 decreased 
the spine volume [65]. Most recently, using activity profiling, 7 additional depalmitoylating 
enzymes; FASN, PNPLA6, ABHD6, ABHD16A ABHD17A/B/C, which belong to serine 
hydrolase group have been identified [66]. Among these novel depalmitoylating enzymes, 
ABHD17, in particular, were reported to control palmitate turnover on post-synaptic density 95 
(PSD95) [66] and diminish the abundance of palmitoylated PSD95 population in neurons, 
therefore, it affects synaptic function by altering synaptic clustering of PSD95 and AMPA 
receptors [67].  
PPT1, a member of PPTs, was first purified from bovine brain as a depalmitoylating enzyme 
of HRAS [61]. Second member of PPTs; PPT2, shares 18% homology with PPT1 [68]. 
Importantly disruption of PPT1 and PPT2 is associated with severe lysosomal storage 
disorder, Neuronal Ceroid Lipofuscinosis (NCL) [69]. PPT1 is also detected in presynaptic 
compartments, suggesting a potential role for PPT1 in retaining the synaptic vesicle pool [70, 
71]. On the other hand, the role of depalmitoylating enzymes in cardiovascular physiology and 
cardiac pathologies remains shrouded in mystery. 
 
3. NCX1 Palmitoylation  
Cardiac sodium/calcium exchangers; NCX1, is a key player in calcium homeostasis by 
mediating bidirectional Na+-Ca2+ exchange in an electrogenic manner. NCX1 structure 
consists of 10 TM domains with a large intracellular loop between TM5 and TM6 (Figure 2A). 
Within the TMDs there are two α repeats that sit between TM2 and TM3 and between TM7 
and TM8 [72, 73]. The large intracellular loop of NCX1 is composed of an Exchanger Inhibitory 
Peptide (XIP) region [74] and Calcium Binding Domains (CBD; CBD1 and CBD2) [75, 76] 
which regulate its function. Two CBDs share a similar structure and interact with regulatory 
Ca2+. CBD1 facilitates Ca2+ dependent activation of NCX1 and coordinates four Ca2+ while 
CBD2 promotes Ca2+ dependent alleviation of Na+ induced inactivation and harbour 2 Ca2+ 
[75, 77]. The intracellular loop of NCX1 also accommodates XIP domain, which corresponds 
to 20 amino acids (219-238aa) and exerts an auto-inhibitory mechanism [74, 78]. Besides 
these insights into structure of NCX1 and its relation to the function, there are other cellular 
signalling pathways which modulate physiology of NCX1. Palmitoylation but no other 
posttranslational modifications have been found to directly regulate NCX1 activity [79, 80]. 
The role of phosphorylation in NCX1 function remains controversial [81-83]. 
 
3.1 Insights into the Mechanism of NCX1 Palmitoylation 
NCX1 contains multiple cysteine residues in its large intracellular loop but surprisingly only 1 
of those, at position 739 at the C-terminal end of the loop, is palmitoylated (Figure 2B). A 
single mutation of this palmitoylation site from Cys- to Alanine (Ala-, A) leads to complete loss 
of palmitoylation of NCX1 [79, 80].  
Mutagenesis scanning around this site by introducing Ala- at following positions; 735, 736, 
737, 738, 740, 741, 742 and 743, are almost entirely without effect on NCX1 palmitoylation. 
Notably, a validated single nucleotide polymorphism (SNP) of NCX1; rs373510583 that 
generates mutation S738F, enhances NCX1 palmitoylation, likely by interfering with its 
depalmitoylation [84, 85]. Near the palmitoylation site, between 740 and 756, an α-helix 
structure with a large hydrophobic face and a small hydrophilic face resides (Figure 2C). This 
amphipathic α-helix, originally thought to form one of the NCX1 transmembrane domains, 
governs NCX1 palmitoylation but is not required its trafficking. Removing the helix entirely 
(Figure 2D) or disrupting either the hydrophobic face by adding negative charges or on the 
hydrophilic face by introducing Ala- abolished or impaired NCX1 palmitoylation (but not 
trafficking) while Ala- mutagenesis on hydrophobic face did not cause any changes in NCX1 
palmitoylation [84, 85]. These data presented by Plain and colleagues clearly suggest that 
NCX1 palmitoylation is controlled by this element of secondary rather than a primary structure. 
Indeed, introduction of this short α-helix to non-palmitoylated proteins causes their 
palmitoylation. The hydrophilic face of this amphipathic α-helix is probably recognised by the 
NCX1 palmitoylating enzyme.  
No other members of the Ca / cation exchanger superfamily possess a cysteine homologous 
to C739 in their intracellular loops, but the NCX1 palmitoylation site and the amphipathic α-
helix required for NCX1 palmitoylation are conserved amongst most metazoan NCX1 
orthologs (Table 1). NCX1 in bilaterians (with the possible exception of echinoderms, in which 
a cysteine is present within rather than adjacent to the amphipathic α-helix) is therefore likely 
regulated by palmitoylation. The one metazoan phylum to lack the NCX1 palmitoylated 
cysteine, the cnidaria, retains the amphipathic α-helix. Within this helix the histidine and lysine 
on the hydrophilic face (respectively in positions +6 and +13 relative to the palmitoylated 
cysteine, when present) are 100% conserved among NCX1 orthologs. We suggest that during 
metazoan evolution the palmitoylated cysteine was acquired after the amphipathic α-helix. 
Interestingly, NCX2 and NCX3, which have analogous palmitoylation sites to C739 in NCX1, 
also possess the same amphipathic helix but with a cysteine at the C terminal end as well and 
the N terminal end. 
 
3.2 Palmitoylation and NCX1 trafficking and subcellular distribution 
A fusion protein between YFP and the NCX1 intracellular loop (excluding the XIP domain but 
including the palmitoylation site) is localised to the Golgi apparatus in transiently transfected 
cells, but adopts a cytosolic distribution if the palmitoylation site is removed [79, 80]. This 
strongly implicates Golgi-localised zDHHC-PATs as being responsible for palmitoylating and 
confining this fusion protein to the Golgi apparatus. Since the Golgi is a cellular ‘hub’ of 
palmitoylation [37, 86] containing high-activity, low-specificity zDHHC-PATs such as zDHHCs 
3 and 7 [87], we do not rule out that other low-activity, high-specificity zDHHC-PATs can 
palmitoylate NCX1 in other cellular compartments. Importantly palmitoylation is not required 
for passage of NCX1 through the secretory pathway. Wild type and unpalmitoylatable NCX1 
reach the cell surface equally [79], which strongly implies that palmitoylation acts as a 
modulator of NCX1 activity upon its arrival at the cell surface. Palmitoylation controls the 
affinity of cytoplasmic and single pass membrane domain proteins for lipid rafts [88, 89], but 
caveolae prepared for ventricular myocyte lysates contain both palmitoylated and non-
palmitoylated NCX1 [79]. This suggests that palmitoylation does not sort NCX1 to cardiac 
caveolae but does not rule out more subtle effects on NCX1 membrane distribution. 
 
4. NCX1 Inactivation 
Na+, Ca2+ and H+ are major allosteric regulators of NCX1 [90, 91]. Each regulator prompts a 
different physiological state in NCX1; (1) Increase in cytosolic Na+ under conditions such as 
ischemia [92] and metabolic stress [93] drives NCX1 to “inactive state”, a process termed Na+ 
dependent inactivation, which limits Ca2+ influx. (2) Binding of Ca2+ to CBDs; with a high affinity 
to CBD1 (Kd ~ 140-400nM) and a lower affinity to CBD2, evokes Ca2+ dependent activation 
[94]. (3) H+ acts as an additional regulator of NCX1 in cardiac tissue [94-97] possibly by 
modulating Ca2+ affinity of CBD1 [91], but also through a direct effect on histidine residues 
outside the NCX1 large intracellular regulatory loop [98]. 
 
4.1 Mechanisms Underlying “Inactive States” of NCX1 
The typical NCX1 current observed in excised patch clamp experiments in response to 
application of Na+ reaches the peak amplitude then decays over 10-20s to a steady-state 
which is 10%-15% of peak amplitude [99]. NCX1 inactivation triggered by Na+ requires either 
an interaction with CBDs [91, 100] or XIP region [78]. Moreover Na+ dependent inactivation 
can be manipulated by; (1) chymotrypsin application, which proteolyses the regulatory loop, 
(2) high cytosolic Ca2+ (above 5µM), (3) ATP (mM concentration range). Once the inactivation 
decay of the NCX1 current has been initiated by Na+, introduction of ATP to cytosolic side 
stimulates an “active state” of the exchanger. This positive regulatory effect of ATP on NCX1 
current was eliminated by phosopholipase C (PLC) treatment but the presence of additional 
phosphatidylinositol 4,5-biphosphate (PIP2) rescued the positive regulatory effect of ATP [99]. 
This is a strong evidence that PIP2 positively increases NCX1 (reverse mode) activity by 
abolishing NCX1 inactivation. Later, it has been also demonstrated that PIP2 binds to NCX1 
at the XIP domain [101].  
In order to inactivate NCX1 the XIP domain interacts with a binding site which also resides 
within the NCX1 intracellular loop. Mutagenesis and electrophysiological studies have 
identified residues 562-679aa [102, 103] as being required for XIP to inactivate NCX1. This 
relatively large region of the NCX1 intracellular loop includes part of CBD2: it is likely that 
‘minimal’ XIP binding site is smaller, but it is yet to be identified,  The interaction between the 
XIP domain and this binding site elicits the NCX1 “inactive state” as an auto-regulatory 
mechanism. Mutagenesis strategies targeting the XIP domain to understand the molecular 
nature of inactive NCX1-phenotype determined that point mutation at position 229 from Lysine 
(Lys-, K) to Glutamine (Gln-, Q); K229Q, leaves NCX1 insensitive to inactivation. In contrast, 
Phenylalanine (Phe-, F) to Glutamic acid (Glu-, E) mutation at position 223; F223E, causes 
NCX1 to be more sensitive to Na+ depended inactivation [78]. Auto-inhibition by XIP can be 
mediated by changes in cellular PIP2 [99, 101, 104]. Tuning NCX1 inactivation by PIP2 relies 
on a physical interaction with the XIP domain [101]. A second lipid species, Acyl CoA esters, 
have also been identified as endogenous regulators of NCX1 inactivation [105].  
 
4.2 Palmitoylation and NCX1 Inactivation 
Besides the modulation of NCX1 inactivation by anionic lipid molecules, palmitoylation was 
found to be critical for NCX1 to achieve a complete inactivation [79, 80]. In cellular models 
expressing wild type and unpalmitoylatable NCX1, inactivation could be triggered by targeting 
either CBDs by Ca2+ depletion (Figure 3A) or XIP by manipulating cellular PIP2 levels (Figure 
3B). Complete chelation of cytosolic Ca2+ completely inhibited NCX1 current over 4 min in wild 
type (WT) exchanger expressing tetracycline inducible stable cell lines, however, there was a 
still leftover current about 22% of amplitude of the initial NCX1 current in unpalmitoylatable 
(C739A) NCX1. Similar to this finding, in the absence of ATP in the cytoplasmic side PLC 
activation via a Ca transient whilst patch clamp recording caused 90% inhibition of WT-NCX1 
current in a subsequent activation cycle while inhibition was about 30% in C739A-NCX1 
current. Furthermore masking anionic PIP2 phospholipid heads using either heptalysine or 
EGTA/Al3+ conjugates led remarkable inhibition of WT-NCX1 current but not in 
unpalmitoylatable [79, 80]. In the light of these findings, palmitoylation can be concluded as a 
key element for NCX1 inactivation.  
The molecular events underlying Na dependent inactivation of NCX1 remain incompletely 
understood. This form of NCX1 inactivation requires the large intracellular loop (because it is 
abolished by chymotrypsin application [106] or the mutation K229Q in the XIP domain [78]), 
but does not directly involve Na interacting with the CBDs. Indeed, histidine residues in the 
linkers between transmembrane domains 2 & 3 and 3 & 4 appear to be involved in the Na-
dependent inactivation process [98, 107]. Notably, palmitoylation facilitates NCX1 inactivation 
whether it is induced by depletion of calcium or PIP2 [79, 80]. This finding suggests that 
palmitoylation facilitates the ‘endpoint’ of NCX1 inactivation – that is, the interaction of XIP 
with its binding site within the NCX1 large intracellular loop, rather than tuning the sensitivity 
of NCX1 to any one particular type of inactivation.  
Ca regulation of NCX1 is a complex process. Occupancy of the Ca binding sites on CBD1 
activates NCX1, whereas Ca binding to CBD2 relieves Na-dependent inactivation [75]. The 
fact that intracellular Ca activates wild type and unpalmitoylatable NCX1 with equal potency 
[79] suggests that palmitoylation at C739 does not influence the regulatory effect of CBD1. 
Indeed the NCX1 palmitoylation site is positioned such that the effect of palmitoylation will be 
to modify conformational flexibility between CBD2 and the sixth transmembrane domain 
(TMD6). By pinning a region of the CBD2-TMD6 linker to the membrane, palmitoylation likely 
changes the ability of CBD2 to influence the movement of this transmembrane domain, and 
ultimately therefore the ability of CBD2 to influence activity. This is consistent with the principal 
functional effect being on NCX1 inactivation. Given the extensive alternative splicing around 
CBD2 in NCX1 [108], it remains to be seen whether the influence of palmitoylation varies for 
different NCX1 splice variants. The palmitoylation site is retained in all NCX1 splice variants, 
but all functional work to date has focussed on the cardiac splice variant. 
The extent of Na+ dependent inactivation of NCX1 differs based on the cell type examined [22, 
106]. Interestingly, NCX1 was also found to be palmitoylated at different levels in various cell 
types. Approximately 60% of total NCX1 population in rat ventricular myocytes was 
palmitoylated at most compare to of those in either stably- or transiently- NCX1 transfected 
HEK293, BHK and HeLa cells [79, 80]. Hence, these differences in NCX1 inactivation could 
be possibly due to the diversity of NCX1 palmitoylation in different cellular models.  
 
4.3 Cargo-dependent endocytosis and NCX1 palmitoylation 
Independent of its effect on NCX1 inactivation, a second phenotype is evident connected to 
NCX1 palmitoylation: the internalisation of membrane domains driven by either Ca overload 
or G protein activation is significantly accelerated in the presence of palmitoylated NCX1 [79]. 
This enigmatic endocytic mechanism was first described as ‘massive endocytosis’ in cells 
following Ca overload, and leads to internalisation of >50% of the surface membrane in only 
a few minutes [109-111]. The signalling pathways underlying this phenomenon remain 
incompletely understood. The release of CoA from mitochondria, the formation of palmitoyl 
CoA in the cytoplasm, and the activity of the surface membrane acyl transferase zDHHC5 to 
palmitoylate integral membrane proteins are all important events in the process [80, 112-115]. 
Ultimately this process is driven not by the presence of one particular palmitoylated cargo, but 
by an abundance of any palmitoylated integral membrane protein. Together the high affinity 
of palmitoylated proteins for curved membranes [116], the ability of palmitoylated proteins to 
induce membrane curvature [117], and phase separation of the membrane ultimately leads to 
clustering and internalisation of proteins - particularly those possessing (or interacting with 
proteins possessing) bulky intracellular regions such as NCX1. When NCX1 is not 
palmitoylated the rate and extent of surface membrane internalisation is significantly slower 
[79], strongly implicating the presence of a palmitoylated ‘cargo’, but not the activity of this 
cargo in the endocytic process. 
The physiological importance of these endocytic events is not entirely clear. Simply preventing 
the release of CoA from mitochondria increases cell size [112], suggesting a role for CoA-
driven endocytosis in ‘resting’ membrane turnover – albeit not entirely in keeping with the 
enormous capacity of this pathway to remodel the surface membrane. Cellular injury induced 
by Ca overload is reduced when the massive endocytosis pathway is inhibited [113], 
suggesting the preferential loss of pumps and transporters from the surface membrane is 
responsible for cell death. However, whether palmitoylated NCX1 contributes significantly to 
membrane turnover or cellular injury in the heart is a question that can only be answered with 
genetic knockin models targeting the NCX1 palmitoylation site. 
 
5. Future Perspectives 
It is, now, evident that the palmitoylation status of NCX1 is a determinant factor for its 
physiology and controlled by the secondary structure. Indeed, this is only a small piece of a 
bigger puzzle and requires more questions to be addressed for a broad mechanistic insight 
into the molecular nature of NCX1 palmitoylation and its physiological consequences. 
What is more to do? 
(1) Palmitoylation/Depalmitoylation Mechanism(s) 
Regarding the mechanism of NCX1 palmitoylation, all that we know so far is that an 
amphipathic α-helix near the palmitoylation site is a structural element controlling NCX1 
palmitoylation. On the other hand, how NCX1 is palmitoylated and depalmitoylated, whether 
its palmitoylation is merely linked to its passage through the secretory pathway or occurs 
dynamically at the cell surface,  or which enzymes catalyse palmitoylation/depalmitoylation of 
NCX1 remain unclear. Hence, next focus needs to be dissecting palmitoylating and 
depalmitoylating enzymes interacting with palmitoylation site within intracellular loop of the 
exchanger. 
 
(2) How Palmitoylation Affects Spatial Organization of NCX1 
Palmitoylation/Depalmitoylation processes tune protein trafficking: while dynamic 
palmitoylation modulates compartmentalization of transmembrane proteins, depalmitoylation 
of soluble proteins impacts their membrane release and their diffusion to cytosol. To date, 
there is no clear evidence on how palmitoylation/depalmitoylation affects spatial organization 
of NCX1 in the cell. 
 
(3) Molecular Basis of Palmitoylation Dependent-Inactivation of NCX1 
Non-palmitoylated NCX1 does not inactivate when wild type NCX1 does. That could be 
speculated as palmitoylation may have an impact on XIP binding to its interacting domain 
which resides near the palmitoylation site, as it is well established that the interaction between 
XIP domain and its interacting region controls NCX1 inactivation. However, this requires a 
direct evidence on such a tuning mechanism of palmitoylation on interaction of XIP and its 
binding site. 
 
(4) Palmitoylation Status of NCX1 and Cardiac Pathologies 
Abnormal NCX1 function contributes to both contractile abnormalities and arrhythmogenesis 
in cardiac muscle. As palmitoylation is proved to have a remarkable impact NCX1 function by 
modulating its inactivation, this might contribute to the emergence of cardiac pathologies. 
Given the importance of NCX1 inactivation in reducing Ca overload during ischemia-
reperfusion, the palmitoylation status of NCX1 may regulate cellular injury during myocardial 
infarction. Hence investigating the palmitoylation of NCX1 in models of contractile dysfunction 
and ischemia-reperfusion would be indeed helpful to understand the molecular mechanism 
behind the disease phenotype and tailor pharmacological strategies targeting NCX1 
palmitoylation to cope with misregulation of Ca2+ homeostasis and inappropriate contractility.  
 
(5) Palmitoylation of other NCX isoforms 
Significant functional differences exist between NCX1, NCX2 and NCX3 – including in 
properties established to be regulated by palmitoylation. All are regulated by an endogenous 
XIP domain but for example only NCX1 and NCX3 are susceptible to Na-dependent 
inactivation, and Ca binding to CBD2 therefore only alleviates Na-dependent inactivation of 
NCX1 and NCX3 [118]. The palmitoylation site and amphipathic a-helix required for NCX 
palmitoylation are 100% identical between human NCX isoforms, meaning it is highly likely 
that all are regulated by palmitoylation. Indeed both NCX2 and NCX3 have cysteines at both 
ends of the amphipathic a-helix, which may mean that they can be doubly rather than singly 
palmitoylated. If a single palmitoylation event reduces the conformational flexibility of the 
CBD2-TMD6 linker of NCX1 it is likely that double palmitoylation of the same region of NCX2 
and NCX3 would induce even greater conformational inflexibility – effectively pinning both 
ends of the amphipathic a-helix to the membrane. Since the effect of a single palmitoylation 
event is to accelerate NCX1 inactivation by XIP, we speculate that double palmitoylation in 
the same region may have more profound effects on NCX behaviour. Any influence on the tilt 
and/or mobility of TMD6, for example, is likely to directly modify NCX activity, since this 
transmembrane domain is proposed to move substantially during the transitions between 
inward and outward facing conformations of NCX [72, 119]. 
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Table 1: Conservation of the NCX1 palmitoylation site in metazoans. The palmitoylated 
cysteine (highlighted in red) in NCX1 is present in all vertebrates and most invertebrates. The 
amphipathic a-helix required for NCX1 palmitoylation is universally conserved (underlined: the 
amino acids comprising the hydrophilic face of this helix), with the possible exception of D. 
melanogaster, in which a serine is located on the hydrophobic face of the helix. Alignments 
show the NCX isoforms designated as NCX1 for each species with the exception of C. 
elegans. C, teleta and L. gigantea NCX1 sequences obtained from [120]. 
 
  
Phylum Common Name Species NCBI/Uniprot ID Sequence
Ecdysozoa: Arthropoda
Fruit fly D. melanogaster NP_001247215.1 VPSCFSYVSHFVCLFWKVLFAF
Mosquito C. tarsalis JAV31432.1 SPSCADYIMHFLTLFWKIIFAF
Ecdysozoa: Nematoda
Roundworm C. elegans NP_504415.2 EPGCMDYVMHVLTVPWKLTFAT
Hookworm A. ceylanicum ANCCEY_06143 PPTCCDYIMHFMTMPWKLLFAT
Lophotrochozoa: Annelida
Worm C. teleta [120] LPSCMDYVMHFLTLFWKVLFAF
Lophotrochozoa: Mollusca
Squid D. opalescens AAB52920.1 LPSCMDYIMHFVCLFWKVLFAF
Owl Limpet L. gigantea [120] LPSCLDYVMHFLTLFWKLLFAF
Lophotrochozoa: Platyhelminthes
Fluke C. sinensis G7YEK8 LPSCMDYVMHFLTVFWKVLFAF
Flatworm S. mediterranea A0A0H3YIW4 MPSCTQYIFHYLSLFWKILFAF
Deuterostomia: Chordata
Human H. sapiens NP_001106271.1 LPSCFDYVMHFLTVFWKVLFAF
Mouse M. musculus NP_001106269.1 LPSCFDYVMHFLTVFWKVLFAF
Chicken G. gallus NP_001072941.1 LPSCFDYVMHFLTVFWKVLFAF
Zebrafish D. rerio NP_001032179.1 MPSCFDYVMHFLTVFWKVLFAF
Pike-Perch S. lucioperca XP_031171840.1 LPSCFDYVMHFLTVFWKVMFAF
Lizard P. muralis XP_028580782.1 LPSCFDYVMHFLTVFWKVLFAF
Clawed frog X. laevis XP_018120632.1 LPSCFDYVMHFLTVFWKVFFAF
Deuterostomia: Echinodermata
Sea Urchin S. purpuratus W4XTQ8 PPSKMDCIMHFITFFWKVIFAM
Radiata: Cnidaria
Anenome E. pallida XP_020915137.1 PPTYGDYMMHFLTVFWKILFAF
Coral S. pistillata XP_022792788.1 TPTYGDYMMHYLTVFWKLLFAI
Figure 1: Palmitoylation regulates cellular trafficking of proteins.  Palmitoylation of a Cys- 
provides a mechanism for continuous shuttling of target proteins between the plasma 
membrane and Golgi through palmitoylation/depalmitoylation cycles. Trafficking route 





Figure 2: NCX1 structure and palmitoylation site within large intracellular loop. (A) 
Schematic of the exchanger structure shows the position of transmembrane domains and 
components of intracellular loop. The intracellular loop harbours XIP and its interacting 
domain, CBDs and palmitoylation site. (B) Mutagenesis screen on cysteines to search for 
palmitoylation site was followed by purification of palmitoylated NCX1 by resin-assisted 
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capture (adapted from [79], UF: unfractionated lysate, HA: purified palmitoylated proteins). 
NCX1 is palmitoylated at a single Cys- at position 739 and a mutation from Cys- to Ala- at this 
position leads complete loss of palmitoylation. (C) Schematic illustration provides a closer look 
at the NCX1 palmitoylation site. Palmitoylation of NCX1 at position 739 is controlled by an 
amphipathic α-helix residing between residues 740 and 756. (D) Deletion of the α-helix 
abolishes palmitoylation of the NCX1 intracellular loop (adapted from [85], UF: unfractionated 
lysate, HA: purified palmitoylated proteins). 
 
 
Figure 3: Palmitoylation regulates NCX1 inactivation in voltage clamped engineered cell 
lines. (A) Depletion of intracellular Ca2+ inactivates NCX1, however when it is 
unpalmitoylatable (C739), NCX1 inactivation is considerably slower. (B) In the absence of 
intracellular ATP NCX1-mediated Ca influx depletes PIP2 and promotes NCX1 inactivation. 
Unpalmitoylatable NCX1 (C739) remains activate (evidenced by substantial NCX1 mediated 
current upon application of extracellular Ca), while wild type NCX1 was completely inactivated 
by the same protocol (adapted from [79]). 
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